Valuation: Verastem, Inc.

Market Cap 547M 481M 449M 412M 771M 52.44B 790M 5.32B 2.08B 25.95B 2.06B 2.01B 89.7B P/E 2026 *
-3.8x
P/E 2027 * -5.36x
Enterprise Value 382M 336M 314M 288M 539M 36.63B 552M 3.72B 1.45B 18.13B 1.44B 1.4B 62.67B EV / Sales 2026 *
3.75x
EV / Sales 2027 * 1.89x
Free-Float
99.07%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Verastem, Inc.

1 day-3.53%
1 week+0.17%
Current month+57.33%
1 month+58.99%
3 months+10.07%
6 months-3.53%
Current year-22.15%
1 week 5.75
Extreme 5.75
6.46
1 month 3.74
Extreme 3.745
6.46
Current year 3.43
Extreme 3.43
8.88
1 year 3.43
Extreme 3.43
11.24
3 years 2.1
Extreme 2.1
14.22
5 years 2.1
Extreme 2.1
42.96
10 years 2.1
Extreme 2.1
124.2
Manager TitleAgeSince
Chief Executive Officer 65 01/08/2023
Director of Finance/CFO 39 31/10/2022
Chief Tech/Sci/R&D Officer - 18/04/2024
Director TitleAgeSince
Chairman 62 -
Director/Board Member 65 01/08/2023
Director/Board Member 69 03/05/2017
Date Insider Type Main position Quantity % Market Cap.
22/06/26 Sell

Chief Executive Officer

-20,871 0.0339%
22/06/26 Sell

Chief Financial Officer

-4,089 0.0066%
21/05/26 Free

Director

36,000 0.0410%
Change 5-day change 1-year change 3-year change Capi.($)
-3.53%+0.17%-0.17%-41.65% 549M
+0.47%+2.03%+51.54%+70.84% 55.01B
+2.83%+0.04%+38.07%+82.59% 54.24B
+0.54%+0.67%-17.59%-13.47% 23.38B
-0.97%-5.06%+1.35%+383.00% 22.57B
+2.07%+1.44%+23.06%-9.05% 20.19B
-2.15%+0.78%+24.67%-31.03% 17.86B
-2.14%-2.72%+30.26%+536.72% 15.5B
-3.14%-8.09%+160.68%+292.18% 14.2B
-2.09%-1.41%+24.65%+178.74% 14.2B
Average -0.78%+0.07%+33.65%+144.89% 23.77B
Weighted average by Cap. +0.29%-0.19%+35.87%+130.22%

Financials

2026 *2027 *
Net sales 102M 89.51M 83.55M 76.68M 144M 9.76B 147M 991M 387M 4.83B 382M 374M 16.69B 178M 157M 146M 134M 251M 17.08B 257M 1.73B 678M 8.45B 670M 655M 29.22B
Net income -166M -145M -136M -125M -233M -15.85B -239M -1.61B -630M -7.85B -621M -608M -27.12B -142M -125M -117M -107M -200M -13.61B -205M -1.38B -540M -6.73B -533M -522M -23.28B
Net Debt -165M -145M -135M -124M -232M -15.8B -238M -1.6B -628M -7.82B -619M -606M -27.04B -210M -184M -172M -158M -295M -20.08B -303M -2.04B -797M -9.93B -787M -770M -34.34B
Logo Verastem, Inc.
Verastem, Inc. is a late-stage development biopharmaceutical company, which focuses on the development and commercialization of new medicines to improve the lives of patients diagnosed with ras sarcoma (RAS)/ mitogen-activated pathway kinase (MAPK) pathway-driven cancers. Its product candidates include avutometinib and defactinib. Avutometinib is an oral RAF/MEK clamp that inhibits MEK1/2 kinase activities and induces inactive complexes of MEK with A-Raf proto-oncogene, potentially serine/threonine kinase (ARAF), B-Raf proto-oncogene serine/threonine kinase (BRAF) and C-raf proto-oncogene serine/threonine kinase, creating antitumor response through maximal RAS/MAPK pathway inhibition. Defactinib is an oral, selective inhibitor of FAK and proline-rich tyrosine kinase (PYK2), the two members of the focal adhesion kinase family of non-receptor protein tyrosine kinases. FAK and PYK2 integrate signals from integrin and growth factor receptors to regulate cell proliferation.
Employees
102
Date Price Change Volume
30/07/26 $6.010 -3.53% 2,249,734
28/07/26 $6.230 +2.47% 1,275,019
27/07/26 $6.080 +0.50% 2,244,215
24/07/26 $6.050 -2.10% 2,531,721
23/07/26 $6.180 +4.92% 2,193,680
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
6.230USD
Average target price
15.00USD
Spread / Average Target
+140.77%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. VSTM Stock